Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05822128
Other study ID # APHP230377
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 28, 2023
Est. completion date October 20, 2023

Study information

Verified date November 2023
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Epworth Sleepiness Scale (ESS) is undoubtedly the most commonly used tool in daily clinical practice to assess daytime sleepiness in patients of all ages by means of a self-administered questionnaire. In elderly subjects, the clinician is often confronted with difficulties in accurately estimating the ESS score and measuring subjective daytime sleepiness. Indeed, according to Onen et al, the ESS tends to underestimate the prevalence of sleep disorders in the geriatric population, mainly due to non-response to problematic items, namely: - Item 3: Sitting, inactive in a public place (cinema, theater, meeting) - Item 8: In a car that has been stopped for a few minutes. In order to overcome this problem, Janine Gronewold's German team has developed and begun work on the validation of an alternative version of the ESS, the ESS-ALT, adapted to the population of interest, in German. The aim of the present work is to adapt the ESS-ALT in French, then to study its correlation with sleep data recorded by nocturnal polysomnography, and among the secondary objectives, to correlate it with sleep latency during iterative sleep latency tests, in order to propose to the clinician a simple, reproducible tool, allowing to measure daytime sleepiness in elderly subjects.


Description:

Developed in 1991 by Dr. Johns at the University of Melbourne and modified by him in 1997, the Epworth Sleepiness Scale (ESS) is undoubtedly the most commonly used tool in daily clinical practice to assess daytime sleepiness in patients of all ages by means of a self-administered questionnaire. In elderly subjects, the clinician is often confronted with difficulties in accurately estimating the ESS score and measuring subjective daytime sleepiness. Indeed, according to Onen et al, the ESS tends to underestimate the prevalence of sleep disorders in the geriatric population, mainly due to non-response to problematic items, namely: - Item 3: Sitting, inactive in a public place (cinema, theater, meeting) - Item 8: In a car that has been stopped for a few minutes. In order to overcome this problem, Janine Gronewold's German team has developed and begun work on the validation of an alternative version of the ESS, the ESS-ALT, adapted to the population of interest, in German. The aim of the present work is to adapt the ESS-ALT in French, then to study its correlation with sleep data recorded by nocturnal polysomnography, and among the secondary objectives, to correlate it with sleep latency during iterative sleep latency tests, in order to propose to the clinician a simple, reproducible tool, allowing to measure daytime sleepiness in elderly subjects


Recruitment information / eligibility

Status Completed
Enrollment 102
Est. completion date October 20, 2023
Est. primary completion date October 19, 2023
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Patient 65 years of age and older - Consulting for sleep disorders - Enrolled in a social security system or entitled to it - Patient informed and having expressed his non-opposition to participate in the research Exclusion Criteria: - Severe psychiatric or cognitive disorders that do not allow the completion of examinations/questionnaires - Patients who are dependent for all acts of daily life - Patients with a very short life expectancy - Patients under guardianship or curatorship - Patients under AME - Patients whose first language is not French - Patients with visual or cognitive impairments that make reading impossible

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Test of an alternative Epworth Sleepiness Scale ESS-ALT in French
Seniors recruited into the study will test the Epworth Alternate Sleepiness Scale -ALT

Locations

Country Name City State
France Hospital Charles Foix Ivry-sur-Seine
France service des pathologies du sommeil, hôpital Pitié Salpêtrière Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Validation of the alternative Epworth Daytime Sleepiness Scale -ALT adapted to the elderly and geriatric population in French forward and backward translation" between English and French, and correlation with the ESS sleepiness scale. 24 hours
Secondary Study of the correlation between the results of the French ESS-ALT and polysomnography data Statistical comparison to identify the intrinsic validity of the ESS-ALT 24 hours
Secondary Study of the correlation between the results of the French ESS-ALT and MSLT (Multiple Sleep Latency Test) data Statistical comparison to identify the intrinsic validity of the ESS-ALT 24 hours
Secondary intrinsic validity of the ESS-ALT in French Statistical comparison to identify the intrinsic validity of the ESS-ALT 24 months
Secondary Study of the correlation between the ESS-ALT cohort in French and the ESS-ALT cohort in Germany Statistical comparison to identify the intrinsic validity of the French version of ESS-ALT 24 months
See also
  Status Clinical Trial Phase
Completed NCT05059223 - A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy Phase 3
Completed NCT04923594 - Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy Phase 2
Completed NCT01072968 - BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP. Phase 3
Completed NCT01620554 - Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA) Phase 2
Completed NCT01067235 - Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy Phase 3
Completed NCT00642928 - Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients Phase 2
Completed NCT00228566 - Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Phase 3
Enrolling by invitation NCT05113745 - A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy Phase 3
Recruiting NCT05939453 - Impact of Bright Light Therapy on Prader-Willi Syndrome N/A
Completed NCT01006122 - A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy Phase 2
Completed NCT02720744 - Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Phase 3
Completed NCT03194217 - BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness Phase 2
Completed NCT01067222 - Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy Phase 3
Completed NCT00228553 - Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness Phase 3
Completed NCT04789174 - Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study Phase 4
Active, not recruiting NCT04886518 - Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Phase 2
Terminated NCT00620659 - Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015) Phase 2
Completed NCT01071876 - BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS Phase 3
Active, not recruiting NCT05458128 - A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia Phase 3
Completed NCT02739568 - Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA Phase 3